Sept. 26, 2005 (Nashville) -- Strontium ranelate is one of the first drugs to have a dual action that both decreases bone resorption and increases bone formation, according to a study presented here ...

Strontium ranelate, a therapeutic for osteoporosis, was thought to have a dual mode of action, simultaneously stimulating bone formation and reducing resorption. A recent study casts doubt on this ...

(HealthDay)—The osteoporosis therapeutic strontium ranelate (SrRan) reduces radiographic and radiological progression of knee osteoarthritis, according to a study presented at the annual meeting of ...

Osteoporosis was originally described in literature and art hundreds of years ago. Our ability to treat this disease lay dormant for centuries, but in the past 10 years, clinical trials have improved ...

London, UK - A new drug for the treatment of osteoporosis, strontium ranelate (Protelos, Servier), was launched this week in the UK and has also been launched in Ireland and Germany. Additional ...

Treating osteoporosis patients with strontium ranelate has been shown to increase the rate of bone formation 17 times over, compared with the preferred treatment. The drug is currently one of NICE’s ...

Strontium ranelate for the treatment of osteoporosis is useful, but changes in bone mineral density need careful interpretation. Nowadays the main treatment options are anti-resorptive agents that ...

UK had licensed the use of strontium ranelate to be used for treating patients with osteoporosis, but scientists caution that before prescribing the drug it is important to observe the changes in the ...

Did you know that strontium, a safe and cheap nutritional supplement, is almost 70% more effective than prescription osteoporosis medications? Loss of bone density, called "osteopenia" when mild and ...

In contrast to previous findings, a nested case–control study did not find evidence of an increased risk of cardiac events associated with the use of strontium ranelate in women with postmenopausal ...

The osteoporosis drug strontium ranelate has been given a last-minute reprieve by Europe’s medicines regulator, following months of speculation as to whether it would be withdrawn from the market.